Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China, according to ...

There’s “quite big news” around weight loss medications circulating right now, says Wajahat Mehal, MD, director of Yale ...

The Danish pharmaceutical giant Novo Nordisk, led by new CEO Maziar Mike Doustdar, is spearheading a radical transformation ...

Low-income Californians who use Wegovy and similar weight loss drugs will lose their coverage in January. California and ...

Novo’s patent on semaglutide, an active ingredient in weight loss drugs like Wegovy, is set to expire in China in March.

Losing weight has always been a major problem for many with different solutions popping up all using varying methods. While ...

Fosun is joining the fray through its subsidiary Yao Pharma, which has granted Pfizer an exclusive worldwide license to ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

The rapid adoption of GLP-1 weight loss medications — drugs like Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound and Mounjaro — is reshaping how Americans eat and shop. It’s also changing ...

A pill from Structure Therapeutics Inc. helped patients lose roughly as much weight as a rival treatment from Eli Lilly & Co., giving the startup an edge as it seeks to break into the highly ...

Current GLP-1 weight-loss meds need to be taken as injections, but new trial results suggest a GLP-1 in pill form could be near In an 18-month clinical trial, people with obesity and diabetes lost ...